| Travis David Whitehead, MD | |
|
6 Player Ct Nw, Rome, GA 30165-2566 | |
| (706) 291-0301 | |
| Not Available |
| Full Name | Travis David Whitehead |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 29 Years |
| Location | 6 Player Ct Nw, Rome, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992748297 | NPI | - | NPPES |
| 053109813A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20444 (South Carolina) | Secondary |
| 207P00000X | Emergency Medicine | 054047 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Health - Good Samaritan Hospital | Mount vernon, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Emergency Good Samaritan, Inc | 1658529342 | 22 |
News Archive
Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.
One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 5 days ago
| Entity Name | Salem Township Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295739548 PECOS PAC ID: 0840195277 Enrollment ID: O20031126000688 |
News Archive
Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.
One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 5 days ago
| Entity Name | Hshs Holy Family Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205850690 PECOS PAC ID: 7517879349 Enrollment ID: O20040216000198 |
News Archive
Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.
One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 5 days ago
| Entity Name | Midwest Emergency Good Samaritan, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629367578 PECOS PAC ID: 1658529342 Enrollment ID: O20120921000645 |
News Archive
Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.
One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 5 days ago
| Entity Name | Midwest Emergency Centralia Campus Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396034245 PECOS PAC ID: 2163672650 Enrollment ID: O20121018000074 |
News Archive
Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.
One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 5 days ago
| Entity Name | Midwest Emergency Sparta, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194162370 PECOS PAC ID: 0345481255 Enrollment ID: O20130718000343 |
News Archive
Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.
One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Travis David Whitehead, MD 6 Player Ct Nw, Rome, GA 30165-2566 Ph: (706) 291-0301 | Travis David Whitehead, MD 6 Player Ct Nw, Rome, GA 30165-2566 Ph: (706) 291-0301 |
News Archive
Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.
One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
› Verified 5 days ago
Peter Ankrom, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 E 2nd Ave, Suite 103, Rome, GA 30161 Phone: 706-509-3278 Fax: 706-509-4608 | |
Paul Keith Shumpert, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 501 Redmond Rd Nw, Rome, GA 30165 Phone: 706-291-0291 | |
Cassandra Evans, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Redmond Rd Nw, Rome, GA 30165 Phone: 706-291-0291 | |
John Kevin Hardwell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 304 Turner Mccall Blvd Sw, Rome, GA 30165 Phone: 706-509-6122 Fax: 706-509-4608 | |
Horace Lee Cline, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 420 E 2nd Ave, Suite 103, Rome, GA 30161 Phone: 706-509-3278 Fax: 706-509-4608 | |
William Scott Alexander Ii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 304 Turner Mccall Boulevard, Floyd Center For Wound Care And Hyperbarics, Rome, GA 30165 Phone: 706-509-5170 | |
David Wyatt Saunders, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Redmond Rd Nw, Rome, GA 30165 Phone: 706-291-0291 |